Please assess the completion status of the following clinical trial:

Trial Title: Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Male or female patients, 40 years of age or older.~* Diagnosis of COPD with a documented post-bronchodilator Forced expiratory volume in one second (FEV1)\< 60% of predicted normal and a post-bronchodilator FEV1/ forced vital capacity (FVC) \<70% at Visit 1~* Documented history of at least one moderate to severe COPD exacerbation in the previous 12 months requiring treatment with systemic corticosteroids and/or antibiotics and/or related hospitalization.~* Symptomatically stable as defined by: no evidence of COPD exacerbation requiring use of either antibiotics and/or steroids 4 weeks prior to visit 1 and no evidence of change in their usual COPD medication 4 weeks prior to visit 1.~* Current or ex-smokers with a smoking history of more than 10 pack years.~Exclusion criteria:~* Significant disease other than COPD.~* Clinically relevant abnormal baseline haematology, blood chemistry or creatinine \> x2 ULN will be excluded regardless of clinical condition. ( A repeat laboratory evaluation can be conducted if deemed necessary by the investigator.)~* Current documented diagnosis of asthma. For patients with allergic rhinitis or atopy, source documentation is required to verify that the patient does not have asthma~* A diagnosis of thyrotoxicosis~* A history of myocardial infarction within 6 months of screening visit.~* Life-threatening cardiac arrhythmia.~* Known active tuberculosis.~* Any malignancy unless free of disease for at least 5 years (patients with treated basal cell carcinoma or squamous cell skin cancers are allowed).~* A history of cystic fibrosis.~* Clinically relevant bronchiectasis.~* Patients with severe emphysema requiring endobronchial interventions within 6 months prior to screening~* A history of significant alcohol or drug abuse in the opinion of the investigator.~* Patients who have undergone thoracotomy with pulmonary resection~* Patients being treated with oral or patch ß-adrenergics.~* Patients being treated with oral corticosteroid medication at unstable doses~* Patients being treated with antibiotics for any reasons within 4 weeks of screening visit~* Patients being treated with PDE4 inhibitors within 3 months of screening visit~* Patients who have taken an investigational drug within one month or six half-lives~* Pregnant or nursing women.~* Women of childbearing potential not using a highly effective method of birth control.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tiotropium + olodaterol high dose (Type: EXPERIMENTAL): Once daily 2 puffs solution for inhalation Respimat
- tiotropium (Type: ACTIVE_COMPARATOR): Once daily 2 puffs solution for inhalation Respimat

Based on this trial design, predict the completion outcome and termination type (if applicable).